EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
ジャーナル・号・ページ	Cell, Vol. 185, Issue 12, Page 2116-2131.e18, Year 2022
掲載日	2022年6月9日
著者	Rungtiwa Nutalai / Daming Zhou / Aekkachai Tuekprakhon / Helen M Ginn / Piyada Supasa / Chang Liu / Jiandong Huo / Alexander J Mentzer / Helen M E Duyvesteyn / Aiste Dijokaite-Guraliuc / Donal Skelly / Thomas G Ritter / Ali Amini / Sagida Bibi / Sandra Adele / Sile Ann Johnson / Bede Constantinides / Hermione Webster / Nigel Temperton / Paul Klenerman / Eleanor Barnes / Susanna J Dunachie / Derrick Crook / Andrew J Pollard / Teresa Lambe / Philip Goulder / / Neil G Paterson / Mark A Williams / David R Hall / Juthathip Mongkolsapaya / Elizabeth E Fry / Wanwisa Dejnirattisai / Jingshan Ren / David I Stuart / Gavin R Screaton /
PubMed 要旨	Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1, and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA. ...Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1, and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly associated with its increased transmissibility. Neutralization differences between sub-lineages for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 binding site; however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following breakthrough Omicron-BA.1 infection reveals that they are focused in two main clusters within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic strains, and many show broad reactivity with variants of concern.
リンク	Cell / PubMed:35662412 / PubMed Central
手法	EM (単粒子) / X線回折
解像度	2.21 - 5.32 Å
構造データ	14885 7zr7 EMDB-14885, PDB-7zr7: OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN 手法: EM (単粒子) / 解像度: 3.7 Å 14886 7zr8 EMDB-14886, PDB-7zr8: OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement) 手法: EM (単粒子) / 解像度: 3.7 Å 14887 7zr9 EMDB-14887, PDB-7zr9: OMI-2 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN 手法: EM (単粒子) / 解像度: 4.0 Å 14910 7zrc EMDB-14910, PDB-7zrc: OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE 手法: EM (単粒子) / 解像度: 3.5 Å PDB-7zf3: SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs 手法: X-RAY DIFFRACTION / 解像度: 3.15 Å PDB-7zf4: SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 手法: X-RAY DIFFRACTION / 解像度: 4.18 Å PDB-7zf5: SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs 手法: X-RAY DIFFRACTION / 解像度: 5.32 Å PDB-7zf6: Omi-12 Fab 手法: X-RAY DIFFRACTION / 解像度: 2.21 Å PDB-7zf7: SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 手法: X-RAY DIFFRACTION / 解像度: 3.46 Å PDB-7zf8: SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab 手法: X-RAY DIFFRACTION / 解像度: 2.95 Å PDB-7zf9: SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21) 手法: X-RAY DIFFRACTION / 解像度: 3.25 Å PDB-7zfa: SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs 手法: X-RAY DIFFRACTION / 解像度: 4.24 Å PDB-7zfb: SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs 手法: X-RAY DIFFRACTION / 解像度: 3.08 Å PDB-7zfc: SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs 手法: X-RAY DIFFRACTION / 解像度: 3.24 Å PDB-7zfd: SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab 手法: X-RAY DIFFRACTION / 解像度: 3.39 Å PDB-7zfe: SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1 手法: X-RAY DIFFRACTION / 解像度: 3.25 Å PDB-7zff: Omi-42 Fab 手法: X-RAY DIFFRACTION / 解像度: 2.32 Å
化合物	ChemComp-GOL: GLYCEROL / グリセロ-ル / グリセリン ChemComp-IPA: ISOPROPYL ALCOHOL / 2-プロパノ-ル / alkaloidYM / 2-プロパノール ChemComp-NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose / N-アセチル-β-D-グルコサミン / N-アセチルグルコサミン ChemComp-SO4: SULFATE ION / 硫酸ジアニオン / 硫酸塩 ChemComp-CIT: CITRIC ACID / クエン酸 / クエン酸 ChemComp-HOH: WATER / 水 ChemComp-ZN*: Unknown entry
由来	severe acute respiratory syndrome coronavirus 2 (SARSコロナウイルス2) homo sapiens (ヒト) tequatrovirus t4 (T4ファージ) enterobacteria phage t4 (ファージ) lama glama (ラマ)
キーワード	VIRAL PROTEIN (ウイルスタンパク質) / SARS-CoV-2 (SARSコロナウイルス2) / Omicron (Ο) / RBD / antibody (抗体) / Fab / Omi-3 / EY6A / VIRAL PROTEIN/IMMUNE SYSTEM (ウイルス性) / BA.1 (SARSコロナウイルス2-オミクロン株) / BA.2 (SARSコロナウイルス2-オミクロン株) / Omi-12 / Beta-54 / IMMUNE SYSTEM (免疫系) / receptor (受容体) / ACE2 (アンジオテンシン変換酵素2) / COVOX-150 / Omi-6 / Omi-18 / Omi-31 / Beta / Omi-25 / VIRALPROTEIN/IMMUNE SYSTEM / Omi-32 / Omi-42 / STRUCTURAL PROTEIN (タンパク質) / SARS-COV2 (SARSコロナウイルス2) / SPIKE / GLYCOPROTEIN (糖タンパク質) / B.1.135 / BETA VARIANT (SARSコロナウイルス2-ベータ株) / COMPLEX / NEUTRALISING / CONVALESCENT SERA / IMMUNE SYSTEM COMPLEX (免疫系)